Asthma Market Summary<\/p>\n
The market size for asthma\u00a0was found to be USD 27 billion in the leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] in 2024.
\n The United States accounted for the largest asthma treatment market size, approximately 80% of the total market size in the 7MM in 2024, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
\n There were approximately 57 million diagnosed prevalent cases of asthma in the leading markets, in 2024. This number is further expected to increase many folds by 2034.
\n There were around 5 million pediatric and 21 million adult cases of asthma in the US in 2024, with numbers expected to rise by 2034.
\n Leading asthma\u00a0companies developing emerging therapies, such as GlaxoSmithKline, Areteia Therapeutics, Sanofi, Connect Biopharma, Upstream Bio, Teva Pharmaceuticals, Launch Therapeutics, AstraZeneca, Incyte Corporation, and others, are developing new asthma treatment\u00a0drugs that can be available in the asthma market in the coming years.\u00a0
\n The promising asthma\u00a0therapies in clinical trials include Depemokimab (GSK3511294), Dexpramipexole, BREZTRI AEROSPHERE (BGF; PT-010), Amlitelimab, Rilzabrutinib (SAR444671), Rademikibart (CBP-201), Verekitug (UPB-101), Fluticasone Propionate\/Albuterol Sulfate (TEV-‘248), Tozorakimab, Lunsekimig (SAR443765), Povorcitinib, and others.<\/p>\n
Discover the new asthma treatment @ Asthma Treatment Market<\/a><\/p>\n Key Factors Driving the Growth of the Asthma Market\u00a0<\/p>\n Rising Prevalence of Asthma Driving the Market<\/p>\n Asthma affects millions worldwide, and its prevalence continues to increase due to urbanization, environmental pollution, changing lifestyles, and higher exposure to allergens. According to DelveInsight analysis, the total number of diagnosed prevalent asthma cases is expected to reach 57 million by 2034. Growing patient populations directly drive demand for effective treatments.<\/p>\n Advances in Inhalation and Drug Delivery Technologies Fueling Market Growth<\/p>\n Innovations such as smart inhalers, dry powder inhalers, and breath-actuated devices are improving patient adherence, accuracy, and convenience. These technological advancements enhance treatment outcomes and contribute to the expansion of the asthma treatment market.<\/p>\n Increasing Adoption of Biologics and Targeted Asthma Therapies Will Drive the Market<\/p>\n Severe asthma cases often remain uncontrolled despite conventional treatments, fueling the demand for biologics, such as monoclonal antibodies, that target the IgE, IL-5, and IL-4 pathways. The rising use of precision medicine and personalized therapies is a significant growth driver for the asthma drug market.<\/p>\n Strong R&D Asthma Pipeline and Novel Therapeutic Approaches Will Surge the Market<\/p>\n Several asthma drugs are in the late-stage pipeline, including depemokimab, PT010, and dexpramipexole dihydrochloride, which are expected to generate significant revenue by 2034. Other assets by AstraZeneca, Sanofi, and\u00a0 Connect Pharma are in the early stages of development.<\/p>\n Asthma Market Analysis<\/p>\n Current asthma therapies mainly aim to relieve symptoms, reduce airway inflammation, and prevent lung damage, but they do not alter the course of the disease. For patients with severe asthma, treatment extends beyond inhalers to include inhaled corticosteroids combined with long-term controller medications such as bronchodilators, leukotriene receptor antagonists, long-acting muscarinic antagonists, long-acting beta-agonists (LABAs), and sustained-release theophylline. Oral corticosteroids are often introduced when symptoms and flare-ups persist despite these measures.<\/p>\n The US FDA has also approved several biologics for asthma treatment, including CINQAIR (reslizumab), FASENRA (benralizumab), NUCALA (mepolizumab), DUPIXENT (dupilumab), TEZSPIRE (tezepelumab-ekko), XOLAIR (omalizumab), and OMLYCLO (omalizumab-igec). However, asthma care continues to face limitations due to the absence of disease-modifying options. Current therapies primarily manage symptoms but do not reverse airway remodeling or stop disease progression. Non\u2013type 2 asthma remains particularly underserved, and variable effectiveness, high costs, and limited availability constrain the use of biologics. Additional barriers such as poor adherence, inhaler misuse, frequent exacerbations, underdiagnosis, and a lack of tailored pediatric options further impact outcomes\u2014highlighting the urgent need for precision medicine and more accessible, long-term therapeutic solutions.<\/p>\n Asthma Competitive Landscape<\/p>\n The expected launch of emerging therapies, such as Depemokimab (GSK3511294, phase III), BREZTRI\/TRIXEO (PT010, phase III), Dexpramipexole Dihydrochloride (phase III), TEV-56248 (TEV-248, phase III), Rilzabrutinib (phase II), Rademikibart (CBP-201, phase III), and others, is expected to create a positive impact on the market.\u00a0<\/p>\n GSK3511294 (depemokimab), currently in development for severe eosinophilic asthma, is a humanized monoclonal antibody targeting IL-5. Designed as a novel biologic, it combines high binding affinity with long-acting suppression of IL-5, a cytokine that drives eosinophil growth, activation, and survival\u2014making it an established therapeutic target in patients with elevated eosinophil counts. Unlike existing IL-5 inhibitors, depemokimab has an extended half-life and superior affinity, enabling subcutaneous dosing only once every 26 weeks.<\/p>\n In January 2025, both the European Medicines Agency (EMA) and Japan accepted depemokimab for regulatory review for the treatment of asthma with type 2 inflammation. If approved, it would become the first ultra-long-acting biologic offering 6-month dosing. The applications are supported by results from the SWIFT-1 and SWIFT-2 trials, which demonstrated significant reductions in exacerbations and hospitalizations when used as an add-on therapy in patients with type 2 inflammatory asthma.<\/p>\n PT010, developed by AstraZeneca, is a fixed-dose triple combination delivered via a pressurized metered-dose inhaler (pMDI) using Aerosphere technology. It contains micronized budesonide (an inhaled corticosteroid), glycopyrronium (a long-acting muscarinic antagonist, LAMA), and formoterol fumarate (a long-acting \u03b22-agonist, LABA). Budesonide provides anti-inflammatory effects, glycopyrronium blocks muscarinic M3 receptors to promote bronchodilation, and formoterol rapidly relaxes bronchial smooth muscle with high selectivity for \u03b22 receptors.<\/p>\n AstraZeneca is conducting multiple Phase III studies to evaluate PT010 in patients with severe asthma who remain uncontrolled despite standard care. The therapy is already marketed as BREZTRI AEROSPHERE in the US and Japan, and as TRIXEO in Europe, but is currently only approved for the treatment of chronic obstructive pulmonary disease (COPD).<\/p>\n Dexpramipexole, developed by Areteia Therapeutics, is an oral eosinophil maturation inhibitor for the treatment of eosinophilic asthma. Unlike IL-5 biologics, it works by halting eosinophil development before the myelocyte stage, thereby reducing the number of eosinophils. Phase II studies demonstrated dose-related decreases in eosinophils and improvements in lung function (FEV\u2081), with efficacy comparable to that of IL-5 antibodies. As an oral option, it may provide an alternative to injectables, potentially becoming the first oral therapy for eosinophilic asthma.<\/p>\n The program is in Phase III with three global EXHALE trials (2,875 patients). EXHALE-4 (lung function) is fully enrolled with results expected in Q3 2025, while EXHALE-2 and -3 (focused on exacerbations) are expected to report by late 2026. A launch is targeted for late 2027, with pediatric and Japan-specific trials supporting broader filings.<\/p>\n Rilzabrutinib (SAR444671), developed by Sanofi, is an oral, reversible covalent inhibitor of Bruton’s tyrosine kinase (BTK), a key regulator in B cells and mast cells involved in immune activation. Using Sanofi’s TAILORED COVALENCY platform, the drug is engineered for selective BTK inhibition with minimal off-target activity, providing rapid and sustained anti-inflammatory effects.<\/p>\n At the ATS International Conference, Sanofi reported results from a Phase II proof-of-concept study in patients with moderate to severe asthma who were inadequately controlled on ICS\/LABA. Treatment with rilzabrutinib resulted in fewer loss-of-control events and improved symptom management, accompanied by a favorable safety profile. These results support its progression into Phase III testing with a twice-daily oral dosing regimen.<\/p>\n The anticipated launch of these emerging therapies are poised to transform the asthma market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the asthma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.<\/p>\n Discover more about the asthma drugs market\u00a0@ Anti-Asthma Drugs Market<\/a>\u00a0<\/p>\n Recent Developments in the Asthma Market<\/p>\n In May 2025, AstraZeneca’s fixed-dose triple-combination therapy BREZTRI aerosphere (budesonide\/glycopyrronium\/formoterol fumarate) met all primary endpoints in the Phase III KALOS and LOGOS trials for uncontrolled asthma. Asthma Disease Overview<\/p>\n Asthma is the most prevalent chronic respiratory disorder worldwide. It affects the lung airways, which become swollen and constricted in response to different triggers, making it difficult for air to pass through. The interaction between airway inflammation and structural changes leads to airway hyper-responsiveness (AHR), causing irregular and excessive narrowing of the airways.<\/p>\n Asthma is generally categorized as either intermittent or persistent, with persistent asthma further classified into mild, moderate, or severe forms. A combination of genetic predisposition, environmental exposures, psychological factors, and respiratory infections influences the severity of the disease.<\/p>\n Asthma Epidemiology Segmentation<\/p>\n The asthma epidemiology section provides insights into the historical and current asthma\u00a0patient pool and forecasted trends for the leading markets. Among the 7MM, the US accounted for nearly 26 million of the total diagnosed prevalent cases of asthma, with around 21 million cases in adults in 2024. These cases are expected to increase by 2034.<\/p>\n The asthma\u00a0treatment market report\u00a0proffers epidemiological analysis for the study period 2020\u20132034 in the leading markets [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan], segmented into:<\/p>\n Total Diagnosed Prevalent Cases of Asthma Asthma Market Report Metrics<\/p>\n Details<\/p>\n Study Period<\/p>\n 2020\u20132034<\/p>\n Coverage<\/p>\n 7MM [The United States, the EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan].<\/p>\n Asthma Market CAGR<\/p>\n 1.95\u00a0%<\/p>\n Asthma Market Size in 2024<\/p>\n USD 27 Billion<\/p>\n Key Asthma Companies<\/p>\n GlaxoSmithKline, Areteia Therapeutics, Sanofi, Connect Biopharma, Upstream Bio, Teva Pharmaceuticals, Launch Therapeutics, AstraZeneca, Incyte Corporation, and others<\/p>\n Key Asthma Therapies<\/p>\n Depemokimab (GSK3511294), Dexpramipexole, BREZTRI AEROSPHERE (BGF; PT-010), Amlitelimab, Rilzabrutinib (SAR444671), Rademikibart (CBP-201), Verekitug (UPB-101), Fluticasone Propionate\/Albuterol Sulfate (TEV-‘248), Tozorakimab, Lunsekimig (SAR443765), Povorcitinib, and others<\/p>\n Scope of the Asthma\u00a0Market Report<\/p>\n Therapeutic Assessment: Asthma\u00a0current marketed and emerging therapies Download the report to understand who’s the best in asthma treatment industry\u00a0@\u00a0Asthma Disease Market\u00a0<\/a><\/p>\n ERS Conference 2025<\/p>\n ERS Conference 2025 will take place from 27 September to 1 October at RAI Amsterdam, Europaboulevard, 1079 MW Amsterdam. Reach out to us to learn how we can assist in assessing the market landscape for any respiratory indication, considering changes in country-specific treatment guidelines, evolving epidemiology trends, and the influence of new therapies. If you are looking to expand into new geographies but unsure about pricing your drug, schedule a meeting today to transform your business strategy and unlock new growth opportunities.\u00a0<\/p>\n Schedule a meeting<\/a><\/p>\n Table of Contents<\/p>\n 1<\/p>\n Asthma Market Key Insights<\/p>\n 2<\/p>\n Asthma Market Report Introduction<\/p>\n 3<\/p>\n Asthma Market Overview at a Glance<\/p>\n 3.1<\/p>\n Clinical Landscape Analysis (By Phase, RoA, and Molecule Type)<\/p>\n 3.2<\/p>\n Market Share (%) Distribution of Asthma by Therapy in 2024<\/p>\n 3.3<\/p>\n Market Share (%) Distribution of Asthma by Therapy in 2034<\/p>\n 4<\/p>\n Executive Summary<\/p>\n 5<\/p>\n Key Events<\/p>\n 5.1<\/p>\n American Thoracic Society (ATS) 2025 Conference Insights<\/p>\n 5.2<\/p>\n Upcoming Key Catalysts<\/p>\n 5.3<\/p>\n Key Transactions and Collaborations<\/p>\n 5.4<\/p>\n News Flow<\/p>\n 6<\/p>\n Asthma Disease Background and Overview<\/p>\n 6.1<\/p>\n Introduction<\/p>\n 6.2<\/p>\n Classification<\/p>\n 6.3<\/p>\n Asthma Signs and Symptoms<\/p>\n 6.4<\/p>\n Asthma Etiology and Risk Factors<\/p>\n 6.5<\/p>\n Asthma Pathophysiology<\/p>\n 6.6<\/p>\n Asthma Diagnosis<\/p>\n 6.7<\/p>\n Asthma Treatment<\/p>\n 6.8<\/p>\n Asthma Diagnosis and Treatment Guidelines<\/p>\n 7<\/p>\n Epidemiology and Asthma Market Forecast Methodology<\/p>\n 8<\/p>\n Asthma Epidemiology and Patient Population<\/p>\n 8.1<\/p>\n Key Findings<\/p>\n 8.2<\/p>\n Assumptions and Rationale: The 7MM<\/p>\n 8.2.1<\/p>\n Total Diagnosed Prevalent Cases of Asthma<\/p>\n 8.2.2<\/p>\n Gender-specific Cases of Asthma<\/p>\n 8.2.3<\/p>\n Severity-specific Cases of Asthma<\/p>\n 8.2.4<\/p>\n Type-specific Cases of Severe Asthma<\/p>\n 8.3<\/p>\n Total Diagnosed Prevalent Cases of Asthma in the 7MM<\/p>\n 8.4<\/p>\n The US<\/p>\n 8.5<\/p>\n EU4 and the UK<\/p>\n 8.6<\/p>\n Japan<\/p>\n 9<\/p>\n Asthma Patient Journey<\/p>\n 10<\/p>\n Marketed Asthma Drugs<\/p>\n 10.1<\/p>\n Key Cross of Marketed Asthma Therapies<\/p>\n 10.2<\/p>\n AIRSUPRA (albuterol and budesonide): AstraZeneca\/Avillion<\/p>\n 10.2.1<\/p>\n Product Description<\/p>\n 10.2.2<\/p>\n Regulatory Milestones<\/p>\n 10.2.3<\/p>\n Other Developmental Activities<\/p>\n 10.2.4<\/p>\n Summary of Pivotal Trials<\/p>\n 10.2.5<\/p>\n Ongoing Clinical Development Activity<\/p>\n 10.2.6<\/p>\n Analyst Views<\/p>\n 10.3<\/p>\n TEZSPIRE (tezepelumab): Amgen\/AstraZeneca<\/p>\n 10.4<\/p>\n TRIMBOW (beclometasone dipropionate, formoterol fumarate, glycopyrronium): Chiesi Farmaceutici<\/p>\n 10.5<\/p>\n ENERZAIR BREEZHALER (indacaterol\/glycopyrronium bromide\/mometasone): Novartis<\/p>\n 10.6<\/p>\n ATECTURA BREEZHALER (indacaterol\/mometasone): Novartis<\/p>\n 10.7<\/p>\n TRELEGY ELLIPTA (FF\/UMEC\/VI): GSK\/Innoviva<\/p>\n 10.8<\/p>\n DUPIXENT (dupilumab): Sanofi\/Regeneron Pharmaceuticals<\/p>\n 10.9<\/p>\n FASENRA (benralizumab): AstraZeneca<\/p>\n 10.10<\/p>\n CINQAIR\/CINQAERO (reslizumab): Teva Pharmaceuticals<\/p>\n 10.11<\/p>\n NUCALA (mepolizumab): GlaxoSmithKline (GSK)<\/p>\n 10.12<\/p>\n ARNUITY ELLIPTA (fluticasone furoate inhalation powder): GSK<\/p>\n 10.13<\/p>\n SPIRIVA RESPIMAT (tiotropium bromide inhalation spray): Boehringer Ingelheim<\/p>\n 10.14<\/p>\n BREO\/RELVAR ELLIPTA (fluticasone furoate\/vilanterol): GSK\/Innoviva<\/p>\n 11<\/p>\n Emerging Asthma Drugs<\/p>\n 11.1<\/p>\n Key Cross Competition<\/p>\n 11.2<\/p>\n Depemokimab (GSK3511294): GlaxoSmithKline<\/p>\n 11.2.1<\/p>\n Product Description<\/p>\n 11.2.2<\/p>\n Other Development Activities<\/p>\n 11.2.3<\/p>\n Clinical Development<\/p>\n 11.2.4<\/p>\n Safety and Efficacy<\/p>\n 11.2.5<\/p>\n Analyst Views<\/p>\n 11.3<\/p>\n Dexpramipexole: Areteia Therapeutics<\/p>\n 11.4<\/p>\n BREZTRI AEROSPHERE (BGF; PT-010): AstraZeneca<\/p>\n 11.5<\/p>\n Amlitelimab: Sanofi<\/p>\n 11.6<\/p>\n Rilzabrutinib (SAR444671): Sanofi<\/p>\n 11.7<\/p>\n Rademikibart (CBP-201): Connect Biopharma<\/p>\n 11.8<\/p>\n Verekitug (UPB-101): Upstream Bio<\/p>\n 11.9<\/p>\n Fluticasone Propionate\/Albuterol Sulfate (TEV-‘248): Teva Pharmaceuticals\/Launch Therapeutics<\/p>\n 11.10<\/p>\n Tozorakimab: AstraZeneca<\/p>\n 11.11<\/p>\n Lunsekimig (SAR443765): Sanofi<\/p>\n 11.12<\/p>\n Povorcitinib: Incyte Corporation<\/p>\n 12<\/p>\n Asthma Market \u2013 7MM Market Analysis<\/p>\n 12.1<\/p>\n Key Findings<\/p>\n 12.2<\/p>\n Key Asthma Market Forecast Assumptions<\/p>\n 12.3<\/p>\n Asthma Market Outlook<\/p>\n 12.4<\/p>\n Attribute Analysis<\/p>\n 12.5<\/p>\n Total Market Size of Asthma in the 7MM<\/p>\n 12.6<\/p>\n Market Size of Asthma by Therapies in the 7MM<\/p>\n 12.7<\/p>\n United States Asthma Market Size<\/p>\n 12.7.1<\/p>\n Total Market Size of Asthma in the US<\/p>\n 12.7.2<\/p>\n Market Size of Asthma by Therapies in the US<\/p>\n 12.8<\/p>\n EU4 and the UK Asthma Market Size<\/p>\n 12.9<\/p>\n Japan Asthma Market Size<\/p>\n 13<\/p>\n Key Opinion Leaders’ Views on Asthma\u00a0<\/p>\n 14<\/p>\n Asthma Market Unmet Needs<\/p>\n 15<\/p>\n Asthma Market SWOT Analysis<\/p>\n 16<\/p>\n Asthma Market Access and Reimbursement<\/p>\n 16.1<\/p>\n The United States<\/p>\n 16.2<\/p>\n EU4 and the UK<\/p>\n 16.3<\/p>\n Japan<\/p>\n 16.4<\/p>\n Market Access and Reimbursement of Asthma<\/p>\n 17<\/p>\n Acronyms and Abbreviations<\/p>\n 18<\/p>\n Bibliography<\/p>\n 19<\/p>\n Asthma Market Report Methodology<\/p>\n Related Reports<\/p>\n Asthma Pipeline<\/a><\/p>\n Asthma\u00a0Pipeline Insight \u2013\u00a02025\u00a0report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key asthma companies, including\u00a0Mabpharm Limited, Avillion LLP, GlaxoSmithKline, Immunotek SL, AB Science, AstraZeneca, Inmunotek, Sterna Biologics, Verona Pharma, MediciNova, Foresee Pharmaceuticals, T-Balance Therapeutics, Teva Pharmaceutical Industries, Aldeyra Therapeutics, Trio Medicines, AstraZeneca, Cumberland Pharmaceuticals, Concentrx Pharmaceuticals, Tetherex Pharmaceuticals, SolAeroMed, Palobiofarma, Sanofi, Oneness Biotech, Novartis, Keymed Biosciences, Suzhou Connect Biopharmaceuticals, 4D Pharma Plc, Hoffman-La-Roche, Celltrion, Glenmark Pharmaceuticals, Archivel Farma, Siolta Therapeutics, Areteia Therapeutics, TFF Pharmaceuticals, Evelo Biosciences, Sunshine Guojian Pharmaceutical, Mabwell (Shanghai) Bioscience, Kinaset Therapeutics, Akari Therapeutics, KLUS Pharma, Upstream Bio, LEO Pharma, among others.<\/p>\n Severe Asthma\u00a0Market<\/a><\/p>\n Severe Asthma\u00a0Market Insights, Epidemiology, and Market Forecast \u2013 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key severe asthma companies including AstraZeneca plc, GlaxoSmithKline plc, Sanofi S.A., Novartis AG, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals, Inc., Johnson & Johnson, Pfizer Inc., Bristol Myers Squibb, Eli Lilly and Company, Vertex Pharmaceuticals Incorporated, Amgen Inc., AbbVie Inc., Genentech, Inc., Gilead Sciences, Inc., Biogen Inc., CSL Limited, among others.<\/p>\n Chronic Obstructive Pulmonary Disease\u00a0Market<\/a><\/p>\n Chronic Obstructive Pulmonary Disease\u00a0Market Insights, Epidemiology, and Market Forecast \u2013 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key COPD companies including Genentech, Inc., GlaxoSmithKline, Verona Pharma plc, Regeneron Pharmaceuticals, Sanofi, MedImmune LLC, EpiEndo Pharmaceuticals, Tetherex Pharmaceuticals, AstraZeneca, Chiesi Farmaceutici S.p.A., Synairgen Research Ltd., Mereo Biopharma, Organicell Regenerative Medicine, Pulmotect, Inc., Inmunotek S.L., PULMATRiX, GLENMARK PHARMACEUTICALS LTD, Dimerix Limited, ProterixBio, among others.<\/p>\n Acute Respiratory Distress Syndrome Market<\/a><\/p>\n Acute Respiratory Distress Syndrome Market Insights, Epidemiology, and Market Forecast \u2013 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ARDS companies, including MediciNova, Edesa Biotech, Light Chain Biosciences, Boehringer Ingelheim, Genentech, Windtree Therapeutics, Biomarck Pharmaceuticals, Athersys, Healios, Direct Biologics, Biohaven Pharmaceutical, Arch Biopartners, APEPTICO Forschung und Entwicklung GmbH, Staidson (Beijing) Biopharmaceuticals, Veru, Mesoblast Limited, Avalo Therapeutics, Pluristem Therapeutics, ILTOO Pharma, among others.<\/p>\n About\u00a0DelveInsight<\/p>\n DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.\u00a0Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform\u00a0PharmDelve.<\/p>\n Contact Us:
\n In March 2025, the US FDA accepted applications for depemokimab for the treatment of asthma with type 2 inflammation. If approved, it will be the first ultra-long-acting biologic with a 6-month dosing regimen. The submissions were based on positive SWIFT-1 and -2 trial data, showing depemokimab reduced exacerbations and hospitalizations as an add-on therapy versus placebo.<\/p>\n
\n Age-specific Cases of Asthma
\n Gender-specific Cases of Asthma
\n Severity-specific Cases of Asthma
\n Type-specific Severity Cases of Asthma<\/p>\n
\n Asthma\u00a0Market Dynamics:\u00a0Key Market Forecast Assumptions of Emerging Asthma\u00a0Drugs and Market Outlook
\n Competitive Intelligence Analysis:\u00a0SWOT analysis and Market entry strategies
\n Unmet Needs, KOL’s views, Analyst’s views, Asthma Market Access and Reimbursement<\/p>\n
Shruti Thakur \u00a0
info@delveinsight.com<\/a> \u00a0
+14699457679
www.delveinsight.com<\/a>\u00a0<\/p>\n
![\"\"](\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=EN67646&Transmission_Id=202509081731PR_NEWS_EURO_ND__EN67646&DateId=20250908\")
<\/p>\n","protected":false},"excerpt":{"rendered":"The asthma market is projected to see consistent growth driven by the introduction of innovative therapies, dexpramipexole, depemokimab…\n","protected":false},"author":2,"featured_media":10396,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12],"tags":[138,12880,12881,220,111,139,69],"class_list":{"0":"post-10395","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-markets","8":"tag-business","9":"tag-delveinsight-business-research","10":"tag-llp","11":"tag-markets","12":"tag-new-zealand","13":"tag-newzealand","14":"tag-nz"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/10395","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/comments?post=10395"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/10395\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media\/10396"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media?parent=10395"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/categories?post=10395"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/tags?post=10395"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}